[Home] [Reports] [Startups] [ONLINE STORE] [site map]

Methodology

Tissue Engineering and Cell Therapy 2014

Worldwide Markets for Tissue Engineering & Cell Therapy, 2013-2023: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World

300 pages   75 Exhibits   144 Company Profiles   Report #S540   December 2013

This report will detail the status and opportunities for technologies, applications and markets in tissue engineering, cell therapy and tissue/cell transplantation. The report will review the therapeutic tissue engineering, tissue reconstruction, cell therapies, tissue/organ transplantation and related technologies under various stages of commercial development, with an emphasis on tissue engineering and cell therapy as emerging technologies more advanced than autograft or allograft tissue transplantation or organ transplantation. The report will detail the technology development, projected market introduction dates and/or current and forecast market size and competitor shares for products being developed to address trauma and disease spanning applications in cardiovascular, neurological, orthopaedic, urological, skin, dental, ophthalmological, gastrointestinal, organ transplant, cancer and others. The report will detail the status of product development and assesses the current and forecast worldwide market for tissue engineering and cell therapy.

The report will provide 2013 company market share data for North America, European Union, Asia/Pacific and Rest of World and market forecast data by country/region from 2013 to 2023, for the U.S., Rest of North America, Latin America, United Kingdom, France, Germany, italy, Spain, Rest of Europe, Japan, Korea, Rest of Asia/Pacific and Rest of World. The report will establish the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast and assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

Table of Contents

EXECUTIVE SUMMARY

SECTION 1: BACKGROUND

Buyers of this report include:
Cell therapy companies
Tissue engineering companies
Large device multinationals
Venture capital firms
Pharma companies
Angel investors
Industry analysts/consultants
1.1 Overview
1.2 Scope of This Report
1.3 Definitions
1.4 Historical Perspective
1.5 Sector Challenges
1.5.1 Reimbursement Environment
1.5.1.1 United States
1.5.1.2 Latin America
1.5.1.3 European Union
1.5.1.4 Japan
1.5.1.5 Korea
1.5.1.6 China
1.5.2 Global Regulatory Landscape
1.5.2.1 Intellectual Property and Key Patents
1.5.2.2 United States
1.5.2.2.1 Biologics Licensing Application (BLA)
1.5.2.3 Latin America
1.5.2.4 European Union
1.5.2.5 Japan
1.5.2.6 Korea
1.5.2.7 China
1.6 Key Patents and Patent Debates
1.6.1 United States
1.6.2 European Union
1.6.2.1 Brüstle Ruling
1.6.3 Japan
1.6.4 Korea
1.6.5 China
1.7 Tissue Engineering and Cell Therapy Industry
1.7.1 Intensity of Competition
1.7.2 Merger and Acquisition Activity
1.7.3 Market Dynamics
1.7.4 Growth Drivers and Restraints
1.7.5 Investment Levels
1.7.6 Opportunities in Tissue Engineering and Cell Therapy

SECTION 2: CLINICAL DISORDERS AND THERAPY NEEDS

2.1. Cardiovascular and Vascular
2.1.1. Coronary Heart Disease
2.1.2. Myocardial Infarction
2.1.3. Congestive Heart Failure
2.1.4. Dysfunctional Heart Valves
2.1.5. Peripheral Vascular Disorders
2.1.6. Abdominal Aortic Aneurysm
2.1.7. Brain Aneurysm
2.2. Neurological
2.2.1. Stroke
2.2.2. Parkinson’s Disease
2.2.3. Alzheimer’s Disease
2.2.4. Amyotrophic Lateral Sclerosis (ALS)
2.2.5. Epilepsy
2.2.6. Traumatic Brain Injury
2.2.7. Central Nervous System and Spinal Cord Disease
2.3. Orthopedic
2.3.1. Non-Union Fractures
2.3.2. Cartilage Damage and Repair
2.3.3. Ligament Damage
2.3.4. Vertebral Disc Damage
2.4. Urological
2.4.1. Corporal Bodies
2.4.2. Urethra
2.4.3. Bladder
2.5. Skin/Integumentary
2.5.1. Burns
2.5.2. Skin Ulcers
2.5.2.1. Diabetic Foot Ulcers
2.5.2.2. Pressure Ulcers
2.5.2.3. Venous Stasis Ulcers
2.6. Dental
2.6.1. Missing Teeth
2.6.2. Periodontal Disease
2.7. Organ Replacement and Repair
2.7.1. Pancreas
2.7.2. Lung
2.7.3. Liver
2.7.4. Kidney
2.7.5. Others
2.8. Ophthalmology
2.8.1. Cornea
2.8.2. Retina
2.9. General, Gastrointestinal, Gynecologic and Other
2.9.1. Ear repair or replacement
2.9.2. Esophagus
2.9.3. Trachea
2.9.4. Stomach
2.9.5. Small Intestine
2.9.6. Large Intestine
2.9.7. Bladder
2.9.8. Uterus
2.9.9. Other
2.10. Cancer
2.10.1. Hematopoietic Stem Cell Transplantation (HSCT)
2.10.2.Cancers Treated with Cell Therapy
2.11. Autoimmune and Inflammatory Diseases
2.11.1. Multiple Sclerosis
2.11.2. Type 1 Diabetes
2.11.3. Crohn’s Disease
2.11.4. Rheumatoid Arthritis

3. SECTION 3: TECHNOLOGY ADVANCES (APPROVED AND IN DEVELOPMENT)

3.1. The Scientific Foundations of Therapeutic Tissue Engineering
3.1.1. Stem Cells
3.1.2. Pluripotent Cells
3.1.3. The Role of Bioreactors in Tissue Engineering
3.1.3.1. Flat-Bed Perfusion Systems
3.1.3.2. Hollow-Fiber Bioreactor Systems
3.1.3.3. Mammalian Cell Suspension Systems
3.2. Risks and Limitations of Tissue/Organ Transplants
3.2.1. Donor tissue/organ availability and statistics
3.2.2. Donor site morbidity
3.2.3. Risk of infection or spread of human disease
3.2.4. Transplant rejection
3.2.5. Immunosuppressive therapy
3.3. Limitations of Biomaterials and Medical Devices
3.3.1. Poor tissue integration
3.3.2. No growth or adaptation
3.3.3. Adverse reaction with surrounding tissue
3.3.4. Loss of mechanical integrity over time
3.3.5. Increased risk of infection
3.4. Emerging Developments in Tissue Engineering and Cell Therapy
3.4.1. Company Innovations
3.4.2. Innovations Emerging from Academic Research Centers
3.4.3. Corporate-Academic Partnerships
3.4.4. Selected Partnership Opportunities
3.5. Overview of Selected Clinical Trials
3.5.1. Cardiovascular and Vascular
3.5.2. Neurological
3.5.3. Orthopedic
3.5.4. Urological
3.5.5. Skin/Integumentary
3.5.6. Dental
3.5.7. Organ Replacement and Repair
3.5.8. Ophthalmology
3.5.9. General, Gastrointestinal, Gynecologic and Other
3.5.10. Cancer

4. SECTION 4: GLOBAL MARKETS FOR TISSUE ENGINEERING AND CELL THERAPY

4.1. Global Market for Tissue Engineering and Cell Therapy
4.1.1. North American Market for Tissue Engineering and Cell Therapy
4.1.1.1. United States
4.1.1.2. Rest of North America
4.1.2. Latin American Market for Tissue Engineering and Cell Therapy
4.1.3. European Union Market for Tissue Engineering and Cell Therapy
4.1.3.1. United Kingdom
4.1.3.2. France
4.1.3.3. Germany
4.1.3.4. Italy
4.1.3.5. Spain
4.1.3.6. Rest of Europe
4.1.4. Asia-Pacific Market for Tissue Engineering and Cell Therapy
4.1.4.1. Japan
4.1.4.2. Korea
4.1.4.3. Rest of Asia-Pacific
4.1.5. Rest of World Market for Tissue Engineering and Cell Therapy
4.2. Global Market for Cardiovascular and Vascular Tissue Engineering and Cell Therapy
4.2.1. North America
4.2.1.1. United States
4.2.1.2. Rest of North America
4.2.2. Latin America
4.2.3. European Union
4.2.3.1. United Kingdom
4.2.3.2. France
4.2.3.3. Germany
4.2.3.4. Italy
4.2.3.5. Spain
4.2.3.6. Rest of Europe
4.2.4. Asia-Pacific
4.2.4.1. Japan
4.2.4.2. Korea
4.2.4.3. Rest of Asia-Pacific
4.2.5. Rest of World
4.3. Global Market for Neurological Tissue Engineering and Cell Therapy
4.3.1. North America
4.3.1.1. United States
4.3.1.2. Rest of North America
4.3.2. Latin America
4.3.3. European Union
4.3.3.1. United Kingdom
4.3.3.2. France
4.3.3.3. Germany
4.3.3.4. Italy
4.3.3.5. Spain
4.3.3.6. Rest of Europe
4.3.4. Asia-Pacific
4.3.4.1. Japan
4.3.4.2. Korea
4.3.4.3. Rest of Asia-Pacific
4.3.5. Rest of World
4.4. Global Market for Orthopedic Tissue Engineering and Cell Therapy
4.4.1. North America
4.4.1.1. United States
4.4.1.2. Rest of North America
4.4.2. Latin America
4.4.3. European Union
4.4.3.1. United Kingdom
4.4.3.2. France
4.4.3.3. Germany
4.4.3.4. Italy
4.4.3.5. Spain
4.4.3.6. Rest of Europe
4.4.4. Asia-Pacific
4.4.4.1. Japan
4.4.4.2. Korea
4.4.4.3. Rest of Asia-Pacific
4.4.5. Rest of World
4.5. Global Market for Urological Tissue Engineering and Cell Therapy
4.5.1. North America
4.5.1.1. United States
4.5.1.2. Rest of North America
4.5.2. Latin America
4.5.3. European Union
4.5.3.1. United Kingdom
4.5.3.2. France
4.5.3.3. Germany
4.5.3.4. Italy
4.5.3.5. Spain
4.5.3.6. Rest of Europe
4.5.4. Asia-Pacific
4.5.4.1. Japan
4.5.4.2. Korea
4.5.4.3. Rest of Asia-Pacific
4.5.5. Rest of World
4.6. Global Market for Skin/Integumentary Tissue Engineering and Cell Therapy
4.6.1. North America
4.6.1.1. United States
4.6.1.2. Rest of North America
4.6.2. Latin America
4.6.3. European Union
4.6.3.1. United Kingdom
4.6.3.2. France
4.6.3.3. Germany
4.6.3.4. Italy
4.6.3.5. Spain
4.6.3.6. Rest of Europe
4.6.4. Asia-Pacific
4.6.4.1. Japan
4.6.4.2. Korea
4.6.4.3. Rest of Asia-Pacific
4.6.5. Rest of World
4.7. Global Market for Dental Tissue Engineering and Cell Therapy
4.7.1. North America
4.7.1.1. United States
4.7.1.2. Rest of North America
4.7.2. Latin America
4.7.3. European Union
4.7.3.1. United Kingdom
4.7.3.2. France
4.7.3.3. Germany
4.7.3.4. Italy
4.7.3.5. Spain
4.7.3.6. Rest of Europe
4.7.4. Asia-Pacific
4.7.4.1. Japan
4.7.4.2. Korea
4.7.4.3. Rest of Asia-Pacific
4.7.5. Rest of World
4.8. Global Market for Organ Replacement and Repair Tissue Engineering and Cell Therapy
4.8.1. North America
4.8.1.1. United States
4.8.1.2. Rest of North America
4.8.2. Latin America
4.8.3. European Union
4.8.3.1. United Kingdom
4.8.3.2. France
4.8.3.3. Germany
4.8.3.4. Italy
4.8.3.5. Spain
4.8.3.6. Rest of Europe
4.8.4. Asia-Pacific
4.8.4.1. Japan
4.8.4.2. Korea
4.8.4.3. Rest of Asia-Pacific
4.8.5. Rest of World
4.9. Global Market for Ophthalmology Tissue Engineering and Cell Therapy
4.9.1. North America
4.9.1.1. United States
4.9.1.2. Rest of North America
4.9.2. Latin America
4.9.3. European Union
4.9.3.1. United Kingdom
4.9.3.2. France
4.9.3.3. Germany
4.9.3.4. Italy
4.9.3.5. Spain
4.9.3.6. Rest of Europe
4.9.4. Asia-Pacific
4.9.4.1. Japan
4.9.4.2. Korea
4.9.4.3. Rest of Asia-Pacific
4.9.5. Rest of World
4.10. Global Market for General, Gastrointestinal, Gynecological and Other Tissue Engineering and Cell Therapy
4.10.1. North America
4.10.1.1. United States
4.10.1.2. Rest of North America
4.10.2. Latin America
4.10.3. European Union
4.10.3.1. United Kingdom
4.10.3.2. France
4.10.3.3. Germany
4.10.3.4. Italy
4.10.3.5. Spain
4.10.3.6. Rest of Europe
4.10.4. Asia-Pacific
4.10.4.1. Japan
4.10.4.2. Korea
4.10.4.3. Rest of Asia-Pacific
4.10.5. Rest of World

SECTION 5: COMPANY PROFILES

5.1 3DM, Inc.
5.2 AAP Implantante AG
5.3 Aastrom Biosciences, Inc.
5.4 ACell, Inc.
5.5 Acorda Therapeutics Inc.
5.6 Advanced BioHealing Inc.
5.7 Advanced Cell Technology Inc.
5.8 Advanced Medical Solutions Group plc
5.9 Aeolus Pharmaceuticals Inc.
5.10 Aldagen Inc.
5.11 Alexion Pharmaceuticals Inc.
5.12 Allergan, Inc.
5.13 Altiva
5.14 Angioblast Systems Inc.
5.15 Angiotech Pharmaceuticals Inc.
5.16 Apatech/Baxter
5.17 Aperion Biologics
5.18 ARIAD Pharmaceuticals Inc.
5.19 Arteriocyte Medical Systems Inc.
5.20 Arthro-Kinetics
5.21 Athersys Inc.
5.22 AVAX Technologies Inc.
5.23 Avita Medical Ltd.
5.24 Bacterin
5.25 Baxter International, Inc.
5.26 Befutur Biotechnologies
5.27 Beta-Cell NV
5.28 Beta-O2 Technologies Ltd.
5.29 Biocomposites, Otd.
5.30 Biocoral Inc.
5.31 Biofisica, Inc.
5.32 Bioheart, Inc.
5.33 BioLife Solutions, Inc.
5.34 Biomet, Inc.
5.35 BioMimetic Therapeutics, Inc.
5.36 Bio Nova International Pty., Ltd.
5.37 BioSante Pharmaceuticals, Inc.
5.38 BioSyntech, Inc.
5.39 BioTime, Inc.
5.40 BioTissue Technologies AG
5.41 BioVest International, Inc.
5.42 Bonalive Biomaterials, Ltd
5.43 Boston Scientific Corp.
5.44 Brainstorm Cell Therapeutics, Inc.
5.45 Breonics, Inc.
5.46 California Stem Cell, Inc.
5.47 Cambrex Corp.
5.48 Capricor, Inc.
5.49 Capstone Therapeutics Corp.
5.50 Cardium Therapeutics, Inc.
5.51 Celgene Corp.
5.52 Cellerix SA
5.53 CellSeed, Inc.
5.54 Cellular Dynamics International, Inc.
5.55 Cerapedics, Inc.
5.56 Cerco Medical LLC
5.57 co.don AG
5.58 ConMed Linvatec Biomaterials, Inc.
5.59 Cook Group, Inc.
5.60 C.R. Bard, Inc.
5.61 CryoLife, Inc.
5.62 Curis, Inc.
5.63 Curasan AG
5.64 Cyclacel Pharmaceuticals, Inc.
5.65 Cytograft Tissue Engineering, Inc.
5.66 Cytomatrix, Inc.
5.67 Cytonet GmbH & Co., KG
5.68 Cytori Therapeutics, Inc.
5.69 Degradable Solutions AG
5.70 DePuy, Inc.
5.71 Develogen AG
5.72 Evotec AG
5.73 Exactech, Inc.
5.74 Excorp Medical, Inc.
5.75 FibroGen, Inc.
5.76 Fidia Advanced Biopolymers S.r.l.
5.77 Forticell Bioscience, Inc.
5.78 Gamida Cell, Ltd.
5.79 Genentech, Inc.
5.80 Genesis-Biopharma, Inc.
5.81 Genta Inc.
5.82 GenVec, Inc.
5.83 Genzyme Corp. (Sanofi Aventis)
5.84 Geron Corp.
5.85 Glycotex, Inc.
5.86 Hepalife Technologies/Aquamed Technologies, Inc./Alliqua, Inc.
5.87 Histocell Tissue Engineering
5.88 Hospira Inc.
5.89 Humacyte, Inc.
5.90 Hybrid Organ GmbH
5.91 Incytu, Inc.
5.92 Inion Oy
5.93 Innovacell Biotechnologie AG
5.94 Integra LifeSciences Corp.
5.95 Intercytex
5.96 Johnson and Johnson
5.97 Kensey Nash Corp.
5.98 Kerecis
5.99 Kinetic Concepts Inc. (acquired JNJ’s Systagenix in July 2013 for $485 million)
5.100 Kuros Biosurgery AG
5.101 Lifecell Corp.
5.102 Maxcyte, Inc.
5.103 Medtronic, Inc.
5.104 Mesoblast Ltd.
5.105 Musculoskeletal Transplant Foundation Inc.
5.106 Nanofiber Solutions—maybe not—primarily sells scaffolds, stuff to grow cells on
5.107 Nellone Therapeutics, Inc.
5.108 Nephrogen LLC
5.109 Neuralstem
5.110 Neurogeneration
5.111 Organogenesis, Inc.
5.112 Organovo, Inc.
5.113 OrthoVita
5.114 Osiris Therapeutics, Inc.
5.115 Osteotech, Inc.
5.116 Pioneer Surgical Technology
5.117 Pluristem Therapeutics, Inc.
5.118 Polyganics
5.119 Proneuron Biotechnologies, Inc.
5.120 Proxy Biomedical
5.121 Q-Med
5.122 Reinnervate
5.123 Reneuron Group
5.124 Renovo
5.125 Revivicor, Inc.
5.126 RTI Biologics, Inc.
5.127 Selective Genetics
5.128 Sernova Corp.
5.129 Smith & Nephew plc
5.130 Southern Lights Biomaterials
5.131 Stryker Corp.
5.132 Synovis Life Technologies, Inc.
5.133 TEI Biosciences, Inc.
5.134 Tengion, Inc.
5.135 Tepha, Inc.
5.136 Tetec Tissue Engineering Technologies AG
5.137 TiGenix N.V.
5.138 Tissuemed
5.139 UroTiss GmbH
5.140 Viacyte
5.141 Vital Therapeutics, Inc.
5.142 Vitrolife
5.143 Wright Medical
5.144 Zimmer Holdings, Inc.

 

Appendix:  Company Directory

 

 

 

Worldwide Markets for Tissue Engineering & Cell Therapy, 2013-2023: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World

 

Price:  $3,950 (print or PDF; add $200 for both).  Site/Global License also available.

Purchase via online store.

Methodology.
MedMarket Diligence Reports are produced through primary and secondary research. Primary research includes interviews with clinicians and industry representatives for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary research includes gathering data from published sources (annual reports, Securities and Exchange Commission 10K, 10Q and other regulatory filings, federal/state/international datasets, company literature, others) on products and technologies on the market and under development. Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.

Contact: Patrick Driscoll, patrick <at> mediligence <dot> com. Tel: (949) 891-1753.

Refund Policy:
MedMarket Diligence print publications may be returned within 30 calendar days of purchase and must be in re-saleable condition for a refund to be issued. No refunds will be provided for digital products such as PDFs; customers are therefore advised to carefully evaluate information (website samples, descriptions, and information otherwise provided by MedMarket Diligence) on publications prior to purchase.

Copyright 2013 MedMarket Diligence, LLC. All rights reserved.
Revised: 09/2/2013

 

 

 

 

 

Our clients


Or call
+1.949.891.1753
+1.949.627.8099 fax

advanced medical technologies blog

Medtech Startups

Medtech financing archives

 

 
Follow us on Twitter
Follow medmarket

Medtech Startups
Online database of recent medtech startups

 

 

Contact Us